A Unique Technology for a Visual Revolution

Laclarée’s eyeglasses, protected by international patents, utilize exclusive electro-fluidic technology that enables instant autofocus. Unlike progressive lenses, which often require an adaptation period, this innovation provides optimal visual acuity in all situations, restoring natural visual freedom for presbyopic individuals.

Franck Leclere: An Experienced Leader for a New Phase of Growth

With a career marked by executive roles in international groups, Franck Leclere brings recognized expertise in commercial strategy and premium brand development to Laclarée. His experience, particularly as General Manager France & BeLux at De RIGO Group, will be a major asset in structuring the commercialization and positioning Laclarée as a key player in innovative optics.

“Joining Laclarée is an opportunity to contribute to an innovation that will transform the daily lives of millions of people. My goal is to accelerate the market launch of this unique solution while building brand recognition among healthcare professionals and the general public,” states Franck Leclere.

A Strategic Partnership for the Future

Bruno Berge, founder and Chief Scientific Officer of Laclarée, welcomes this appointment: “Franck Leclere’s arrival is excellent news for Laclarée. His experience in general management and deep understanding of the optics market, including internationally, will enable us to take a decisive step in our development. With Franck, we will realize our vision: to offer a revolutionary solution to the millions of people affected by presbyopia, while consolidating our position as a technological leader.”

Unanimous Support from Investors, UI Investissement, HTGF, Rimonci Capital

Richel Liu, founder of Rimonci Capital, emphasizes the importance of this appointment for Laclarée’s future: “We firmly believe in Laclarée’s disruptive technology, which has the potential to redefine visual health standards. Franck Leclere’s arrival at the helm of the company is a major step: his leadership and experience will accelerate the market launch of this innovation while strengthening the confidence of partners and consumers. Laclarée is on track to become a key player in the medical optics field, and we are proud to support this journey.”

Commercial Launch Expected in 2026

After several years of research and user testing, Laclarée is finalizing its first commercial product. The launch, planned for 2026, will rely on a strategy targeting both opticians and end consumers, with the ambition of becoming the reference in adaptive visual correction.